Timing of cytoreductive nephrectomy impacts survival in mRCC

Patients with metastatic renal cell carcinoma who respond to tyrosine kinase inhibitor therapy may have better outcomes if they are treated with this targeted therapy before rather than after cytoreductive nephrectomy, study findings show.

via Med Wire News